The Centers for Medicare & Medicaid Services granted coverage for Personalis’ NeXT Personal minimal residual disease (MRD) test for recurrence monitoring in Medicare beneficiaries with stage II and III breast cancer for up to six years. The decision recognizes a tumor‑informed whole‑genome sequencing assay as a reimbursable surveillance tool. Personalis cited published data in Annals of Oncology showing early detection of recurrence—often more than a year ahead of imaging—in multiple breast cancer subtypes. The CMS decision could accelerate clinical adoption of tumor‑informed MRD testing, influence payer policies beyond Medicare and alter post‑treatment surveillance pathways in precision oncology.